Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation

被引：21
作者：
Kawazoe, Hitoshi
Takiguchi, Yoshiharu
Tanaka, Hiroaki
Fukuoka, Noriyasu
Ohnishi, Hiroaki
Ishida, Toshihiko
Houchi, Hitoshi
机构：
[1] Kagawa Univ Hosp, Dept Pharm, Miki, Kagawa 7610793, Japan
[2] Kagawa Univ, Dept Internal Med, Div Endocrinol & Metab Hematol Rheumatol & Resp M, Fac Med, Miki, Kagawa 7610793, Japan
[3] Univ Tokushima, Dept Clin Pharmacol, Grad Sch Pharmaceut Sci, Tokushima 7708505, Japan
来源：
BIOLOGICAL & PHARMACEUTICAL BULLETIN | 2006年 / 29卷 / 12期
关键词：
voriconazole; tacrolimus; transplantation; concentration; interaction;
D O I：
10.1248/bpb.29.2528
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The purpose of this study was to assess the impact by switching co-administered triazole antifungal agent from fluconazole (FCZ) to voriconazole (VCZ) on the blood concentration of tacrolimus (FK506) in patients receiving allogeneic hematopoietic stem cell transplantation. We performed a retrospective study presented as case reports. The blood concentration of FK506 was increased after the switch from FCZ to VCZ, resulting in increase of the concentration/dose (C/D) ratio of FK506. Thus, the mean C/D ratios of FK506 with oral administration was surprisingly increased over 4.5-fold after the switch. Therefore, it was necessary to reduce the FK506 dose when co-administered FCZ is switched to VCZ. We should be careful when interpreting the results of these case reports; however, in some patients, it is recommended that the dose of FK506 be reduced to one-fifth after the switch.
引用
收藏
页码：2528 / 2531
页数：4
相关论文
共 20 条
[1]  
CAUDRON E, 2003, FUND CLIN PHARM, V17, P183
[2]   Elevated plasma levels of tacrolimus after concurrent use of tacrolimus and voriconazole in the bone marrow transplant setting [J].
Cool, RM ;
Ippoliti, C ;
Cuellar, S ;
Donato, ML .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) :104-104
[3]   Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients [J].
Dykewicz, CA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :139-144
[4]   Voriconazole in the treatment of invasive mold infections in transplant recipients [J].
Fortún, J ;
Martín-Dávila, P ;
Sánchez, MA ;
Pintado, V ;
Alvarez, ME ;
Sánchez-Sousa, A ;
Moreno, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (07) :408-413
[5]  
GILBERT DN, 2005, SANFORD GUIDE ANTIMI, P261
[6]  
*JAP SOC HEM CELL, 2006, JSHCT MON, V3
[7]   Voriconazole [J].
Jeu, L ;
Piacenti, FJ ;
Lyakhovetskiy, AG ;
Fung, HB .
CLINICAL THERAPEUTICS, 2003, 25 (05) :1321-1381
[8]  
Kami Masahiro, 2004, Nihon Ishinkin Gakkai Zasshi, V45, P189, DOI 10.3314/jjmm.45.189
[9]   Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years [J].
Kojima, R ;
Kami, M ;
Kanda, Y ;
Kusumi, E ;
Kishi, Y ;
Tanaka, Y ;
Yoshioka, S ;
Morishima, S ;
Fujisawa, S ;
Mori, S ;
Kasai, M ;
Hatanaka, K ;
Tajima, K ;
Kasai, M ;
Mitani, K ;
Ichinohe, T ;
Hirai, H ;
Taniguchi, S ;
Sakamaki, H ;
Harada, M ;
Takaue, Y .
BONE MARROW TRANSPLANTATION, 2005, 36 (08) :667-674
[10]   Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia [J].
Laughlin, MJ ;
Eapen, M ;
Rubinstein, P ;
Wagner, JE ;
Zhang, MJ ;
Champlin, RE ;
Stevens, C ;
Barker, JN ;
Gale, RP ;
Lazarus, HM ;
Marks, DI ;
van Rood, JJ ;
Scaradavou, A ;
Horowitz, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (22) :2265-2275
12